225 related articles for article (PubMed ID: 30175559)
1. Action potential clamp characterization of the S631A hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Physiol Rep; 2018 Sep; 6(17):e13845. PubMed ID: 30175559
[TBL] [Abstract][Full Text] [Related]
2. Identification through action potential clamp of proarrhythmic consequences of the short QT syndrome T618I hERG 'hotspot' mutation.
Du C; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2022 Mar; 596():49-55. PubMed ID: 35114584
[TBL] [Abstract][Full Text] [Related]
3. Action potential clamp and pharmacology of the variant 1 Short QT Syndrome T618I hERG K⁺ channel.
El Harchi A; Melgari D; Zhang YH; Zhang H; Hancox JC
PLoS One; 2012; 7(12):e52451. PubMed ID: 23300672
[TBL] [Abstract][Full Text] [Related]
4. Functional and pharmacological characterization of an S5 domain hERG mutation associated with short QT syndrome.
Butler A; Zhang Y; Stuart AG; Dempsey CE; Hancox JC
Heliyon; 2019 Apr; 5(4):e01429. PubMed ID: 31049424
[TBL] [Abstract][Full Text] [Related]
5. Electrophysiological characterization of the modified hERG
Zhang Y; Dempsey CE; Hancox JC
Physiol Rep; 2020 Oct; 8(20):e14568. PubMed ID: 33091232
[TBL] [Abstract][Full Text] [Related]
6. Serine mutation of a conserved threonine in the hERG K
Al-Moubarak E; Zhang Y; Dempsey CE; Zhang H; Harmer SC; Hancox JC
Biochem Biophys Res Commun; 2020 Jun; 526(4):1085-1091. PubMed ID: 32321643
[TBL] [Abstract][Full Text] [Related]
7. A novel mutation in the KCNH2 gene associated with short QT syndrome.
Sun Y; Quan XQ; Fromme S; Cox RH; Zhang P; Zhang L; Guo D; Guo J; Patel C; Kowey PR; Yan GX
J Mol Cell Cardiol; 2011 Mar; 50(3):433-41. PubMed ID: 21130771
[TBL] [Abstract][Full Text] [Related]
8. Ranolazine inhibition of hERG potassium channels: drug-pore interactions and reduced potency against inactivation mutants.
Du C; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2014 Sep; 74(100):220-30. PubMed ID: 24877995
[TBL] [Abstract][Full Text] [Related]
9. Comparative effects of the short QT N588K mutation at 37 degrees C on hERG K+ channel current during ventricular, Purkinje fibre and atrial action potentials: an action potential clamp study.
McPate MJ; Zhang H; Adeniran I; Cordeiro JM; Witchel HJ; Hancox JC
J Physiol Pharmacol; 2009 Mar; 60(1):23-41. PubMed ID: 19439805
[TBL] [Abstract][Full Text] [Related]
10. Clemastine, a conventional antihistamine, is a high potency inhibitor of the HERG K+ channel.
Ridley JM; Milnes JT; Hancox JC; Witchel HJ
J Mol Cell Cardiol; 2006 Jan; 40(1):107-18. PubMed ID: 16288909
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of hERG potassium channel blockade by the class Ic antiarrhythmic flecainide.
Melgari D; Zhang Y; El Harchi A; Dempsey CE; Hancox JC
J Mol Cell Cardiol; 2015 Sep; 86():42-53. PubMed ID: 26159617
[TBL] [Abstract][Full Text] [Related]
12. Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs.
McPate MJ; Duncan RS; Hancox JC; Witchel HJ
Br J Pharmacol; 2008 Nov; 155(6):957-66. PubMed ID: 18724381
[TBL] [Abstract][Full Text] [Related]
13. Interactions between amiodarone and the hERG potassium channel pore determined with mutagenesis and in silico docking.
Zhang Y; Colenso CK; El Harchi A; Cheng H; Witchel HJ; Dempsey CE; Hancox JC
Biochem Pharmacol; 2016 Aug; 113():24-35. PubMed ID: 27256139
[TBL] [Abstract][Full Text] [Related]
14. The Susceptibilities of Human Ether-à-Go-Go-Related Gene Channel with the G487R Mutation to Arrhythmogenic Factors.
Hisajima N; Hata Y; Kinoshita K; Fukushima T; Nishida N; Kano M; Tabata T
Biol Pharm Bull; 2015; 38(5):781-4. PubMed ID: 25947924
[TBL] [Abstract][Full Text] [Related]
15. Tbx20 controls the expression of the KCNH2 gene and of hERG channels.
Caballero R; Utrilla RG; Amorós I; Matamoros M; Pérez-Hernández M; Tinaquero D; Alfayate S; Nieto-Marín P; Guerrero-Serna G; Liu QH; Ramos-Mondragón R; Ponce-Balbuena D; Herron T; Campbell KF; Filgueiras-Rama D; Peinado R; López-Sendón JL; Jalife J; Delpón E; Tamargo J
Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E416-E425. PubMed ID: 28049825
[TBL] [Abstract][Full Text] [Related]
16. The N588K-HERG K+ channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 degrees C.
McPate MJ; Duncan RS; Milnes JT; Witchel HJ; Hancox JC
Biochem Biophys Res Commun; 2005 Aug; 334(2):441-9. PubMed ID: 16011830
[TBL] [Abstract][Full Text] [Related]
17. New aspects of HERG K⁺ channel function depending upon cardiac spatial heterogeneity.
Zhang P; Guan P; Bai XL; Song ZP
PLoS One; 2014; 9(1):e72181. PubMed ID: 24475014
[TBL] [Abstract][Full Text] [Related]
18. A Heterozygous Missense hERG Mutation Associated with Early Repolarization Syndrome.
Cheng YJ; Yao H; Ji CC; Chen XM; Fan J; Liu LJ; Wu SH
Cell Physiol Biochem; 2018; 51(3):1301-1312. PubMed ID: 30481776
[TBL] [Abstract][Full Text] [Related]
19. Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation.
Hancox JC; Witchel HJ; Varghese A
Biochem Biophys Res Commun; 1998 Dec; 253(3):719-24. PubMed ID: 9918793
[TBL] [Abstract][Full Text] [Related]
20. Suppression of the hERG potassium channel response to premature stimulation by reduction in extracellular potassium concentration.
Melgari D; Du C; El Harchi A; Zhang Y; Hancox JC
Physiol Rep; 2014 Oct; 2(10):. PubMed ID: 25318749
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]